Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Daiichi Sankyo Co., Ltd.
Primary objective is to evaluate antihypertensive effect and safety of CS-3150 2.5 mg compared to Eplerenone in patients with essential hypertension.
Secondary objective is to evaluate antihypertensive effect and safety of CS-3150 5.0 mg compared to 2.5 mg.
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female subjects aged 20 years or older at informed consent
Subjects with essential hypertension satisfying the following blood pressure criteria;
* Sitting SBP: ≥ 140 mmHg and \< 180 mmHg
* Sitting DBP: ≥ 90 mmHg and \< 110 mmHg
* Mean 24 hr BP: SBP ≥ 130 and DBP ≥ 80 mmHg
You may not be if
Secondary hypertension or malignant hypertension
Diabetic nephropathy or diabetes mellitus with albuminuria
Serum potassium level \< 3.5 or ≥ 5.1 mEq/L
Reversed day-night life cycle including overnight workers